The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: A nationwide cohort study
Abstract
Summary: North American and European guidelines on atrial fibrillation (AF) are conflicting regarding the classification of patients at low/intermediate risk of stroke. We aimed to investigate if the CHA2DS2-VASc score improved risk stratification of AF patients with a CHADS2 score of 0–1. Using individual-level-linkage of nationwide Danish registries 1997–2008, we identified patients discharged with AF having a CHADS2 score of 0–1 and not treated with vitamin K antagonist or heparin. In patients with a CHADS2 score of 0, 1, and 0–1, rates of stroke/ thromboembolism were determined according to CHA2DS2-VASc score, and the risk associated with increasing CHA2DS2-VASc score was estimated in Cox regression models adjusted for year of inclusion and anti-platelet therapy. The value of adding the extra CHA2DS2-VASc risk factors to the CHADS2 score was evaluated by c-statistics, Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI). We included 47,576 patients with a CHADS2 score of 0–1, from these 7,536 (15.8%) were CHA2DS2-VASc score=0, 10,062 (21.2%) were CHA2DS2-VASc score=1, 14,310 (30.1%) were CHA2DS2-VASc score=2, 14,188 (29.8%) were CHA2DS2-VASc score=3, and 1,480 (3.1%) were CHA2DS2-VASc score=4. Of the cohort with a CHADS2 score of 0–1, the stroke/thromboembolism rate per 100 person-years increased with increasing CHA2DS2-VASc score (95% confidence interval): 0.84 (0.65–1.08), 1.79 (1.53–2.09), 3.67 (3.34–4.03), 5.75 (5.33–6.21), and 8.18 (6.68–10.02) at one year follow-up with CHA2DS2-VASc scores of 0, 1, 2, 3, and 4, respectively. Patients with a CHADS2 score=0 were not all ‘low risk’, with one-year event rates ranging from 0.84 (CHA2DS2-VASc score=0) to 3.2 (CHA2DS2-VASc score=3). Results from Cox regression analyses, NRI, and IDI confirmed the improved predictive ability of the CHA2DS2-VASc score in the AF patients who have a CHADS2 score of 0–1. In conclusion, the CHA2DS2-VASc provides critical information on risk of stroke in AF patients with a CHADS2 score of 0–1 that can aid a decision of using anti-coagulation. Even in patients categorised as ‘low risk’ using a CHADS2 score=0, the CHA2DS2-VASc score significantly improved the predictive value of the CHADS2 score alone and a CHA2DS2-VASc score=0 could clearly identify ‘truly low risk’ subjects. Use of the CHA2DS2-VASc score would significantly improve classification of AF patients at low and intermediate risk of stroke, compared to the commonly used CHADS2 score. Note: The editorial process for this article was fully handled by Prof. Christian Weber, Editor-in-Chief.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Self-citationPencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493 · cited 2×
“IDI investigate differences between integrated sensitivity and specificity for models with and without the extra CHA2DS2-VASc covariates (28).”
BackgroundMethodDeveloped with the special contribution of the European Heart Rhythm Association (EHRA), Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), Authors/Task Force Members, Camm, A. J., Kirchhof, P., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Van Gelder, I. C., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,864
Self-citationGage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · Chest · doi:10.1378/chest.10-0134 · Cited by 4,505
Self-citationSystematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
The Danish National Hospital Register. A valuable source of data for modern health sciences.
Andersen, T. F., Madsen, M., Jørgensen, J. O. L., Mellemkjoer, L., & Olsen, J. H. (1999) · PubMed · Cited by 2,026
Olesen, J. B., Lip, G. Y. H., Hansen, M. L., Hansen, P. R., Tolstrup, J. S., Lindhardsen, J., Selmer, C., Ahlehoff, O., Olsen, A.-M. S., Gislason, G. H., et al. (2011) · BMJ · doi:10.1136/bmj.d124 · Cited by 1,428
Self-citationFriberg, L., Rosenqvist, M., & Lip, G. Y. H. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr488 · Cited by 1,192 · cited 1×
“This large ‘real world’ study is consistent with the increasing literature from multiple different cohorts that the CHA2DS2-VASc score is better than CHADS2 score in identifying ‘truly low risk’ patients who do not need any antithrombotic therapy (11, 14, 24, 30).”
ResultSelf-citationFuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Kay, G. N., Le Huezey, J.-Y., Lowe, J. E., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.013 · Cited by 924
Antithrombotic Therapy for Atrial Fibrillation
You, J. J., Singer, D. E., Howard, P. A., Lane, D. A., Eckman, M. H., Fang, M. C., Hylek, E. M., Schulman, S., Go, A. S., Hughes, M., et al. (2012) · Chest · doi:10.1378/chest.11-2304 · Cited by 918
Self-citationHansen, M. L., Sørensen, R., Clausen, M. T., Fog-Petersen, M. L., Raunsø, J., Gadsbøll, N., Gislason, G. H., Folke, F., Andersen, S. S., Schramm, T. K., et al. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.271 · Cited by 855 · cited 1×
“However, we have previously found that aspirin do not decrease stroke risk in ‘real world’ cohorts (24), and our similar studies have been widely recognised despite this potential limitation (40, 41).”
BackgroundAntithrombotic Therapy in Atrial Fibrillation
Singer, D. E., Albers, G. W., Dalen, J. E., Fang, M. C., Go, A. S., Halperin, J. L., Lip, G. Y. H., & Manning, W. J. (2008) · Chest · doi:10.1378/chest.08-0678 · Cited by 751
Self-citationWriting Committee Members, Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., et al. (2006) · Europace · doi:10.1093/europace/eul097 · Cited by 667
Go, A. S., Hylek, E. M., Borowsky, L. H., Phillips, K. A., Selby, J. V., & Singer, D. E. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-12-199912210-00004 · Cited by 585
Sørensen, R., Hansen, M. L., Abildstrom, S. Z., Hvelplund, A., Andersson, C., Jørgensen, C., Madsen, J. K., Hansen, P. R., Køber, L., Torp-Pedersen, C., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61751-7 · Cited by 575
Self-citationThe Danish prescription registries.
Gaist, D., Sørensen, H. T., & Hallas, J. (1997) · PubMed · Cited by 570
Independent predictors of stroke in patients with atrial fibrillation: A systematic review
The Stroke Risk in Atrial Fibrillation Working Group (2007) · Neurology · doi:10.1212/01.wnl.0000267275.68538.8d · Cited by 547
Lip, G., Lindhardsen, J., Lane, D., Ahlehoff, O., Hansen, M., Raunsø, J., Tolstrup, J., Hansen, P., Gislason, G., Torp-Pedersen, C., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-05-0364 · Cited by 428
Self-citationComparing the Predictive Powers of Survival Models Using Harrell's C or Somers’ D
Newson, R. B. (2010) · The Stata Journal: Promoting communications on statistics and Stata · doi:10.1177/1536867x1001000303 · Cited by 424
Validity of Stroke Diagnoses in a National Register of Patients
Krarup, L.-H., Boysen, G., Janjua, H., Prescott, E., & Truelsen, T. (2007) · Neuroepidemiology · doi:10.1159/000102143 · Cited by 366
van Walraven, C., Hart, R. G., Connolly, S., Austin, P. C., Mant, J., Hobbs, F. D. R., Koudstaal, P. J., Petersen, P., Perez-Gomez, F., Knottnerus, J. A., et al. (2009) · Stroke · doi:10.1161/strokeaha.108.526988 · Cited by 312
STEGER, C., PRATTER, A., MARTINEKBREGEL, M., AVANZINI, M., VALENTIN, A., SLANY, J., & STOLLBERGER, C. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.030 · Cited by 303
Banerjee, A., Lane, D. A., Torp-Pedersen, C., & Lip, G. Y. H. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-11-0784 · Cited by 301
Self-citationCairns, J. A., Connolly, S., McMurtry, S., Stephenson, M., & Talajic, M. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.11.007 · Cited by 292
Moving the Tipping Point: The Decision to Anticoagulate Patients With Atrial Fibrillation
Eckman, M. H., Singer, D. E., Rosand, J., & Greenberg, S. M. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.958108 · Cited by 275
VAN STAA, T. P., SETAKIS, E., DI TANNA, G. L., LANE, D. A., & LIP, G. Y. H. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04085.x · Cited by 272
Self-citationOLESEN, J. B., LIP, G. Y. H., HANSEN, P. R., LINDHARDSEN, J., AHLEHOFF, O., ANDERSSON, C., WEEKE, P., HANSEN, M. L., GISLASON, G. H., & TORP‐PEDERSEN, C. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04378.x · Cited by 201
Self-citationBoriani, G., Botto, G. L., Padeletti, L., Santini, M., Capucci, A., Gulizia, M., Ricci, R., Biffi, M., De Santo, T., Corbucci, G., et al. (2011) · Stroke · doi:10.1161/strokeaha.110.609297 · Cited by 183
Self-citationChao, T.-F., Lin, Y.-J., Tsao, H.-M., Tsai, C.-F., Lin, W.-S., Chang, S.-L., Lo, L.-W., Hu, Y.-F., Tuan, T.-C., Suenari, K., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.045 · Cited by 162
The CHADS2 score for stroke risk stratification in atrial fibrillation – friend or foe?
Eikelboom, J. W., & Karthikeyan, G. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0757 · Cited by 146
Lin, L., Lee, C., Yu, C., Tsai, C., Lai, L.-P., Hwang, J., Chen, P., & Lin, J.-L. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.03.033 · Cited by 124
Wallace, E., Dillon, C., Dimitrov, B. D., Fahey, T. P., & Keogh, C. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-02-0061 · Cited by 122
Vascular Disease and Stroke Risk in Atrial Fibrillation: A Nationwide Cohort Study
Olesen, J. B., Lip, G. Y. H., Lane, D. A., Køber, L., Hansen, M. L., Karasoy, D., Hansen, C. M., Gislason, G., & Torp-Pedersen, C. T. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.024 · Cited by 95
Self-citationStroke in atrial fibrillation: epidemiology and thromboprophylaxis
Lip, G. Y. H. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04302.x · Cited by 92
Self-citationTrend in Mortality after Stroke with Atrial Fibrillation
Frost, L., Andersen, L. V., Vestergaard, P., Husted, S., & Mortensen, L. S. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.12.027 · Cited by 86
Gerth, A., Limbourg, T., Lewalter, T., Goette, A., Wegscheider, K., Treszl, A., Meinertz, T., Oeff, M., Ravens, U., BREITHARDT, G. E., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-02-0070 · Cited by 70
Taillandier, S., Olesen, J. B., Clémenty, N., Lagrenade, I., Babuty, D., Lip, G. Y. H., & Fauchier, L. (2012) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2011.02257.x · Cited by 42
Self-citationAbu‐Assi, E., Otero-Raviña, F., Vidal, G., Méndez, A. C., Mosquera, L. V., Loureiro, M. S., Villar, M. C. C., Villaverde, J. M. F., Saavedra, F. J. M., & González‐Juanatey, J. R. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.10.096 · Cited by 33
Cited by
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
Self-citationKleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
Metadata
- Authors
- Olesen, J., Torp-Pedersen, C., Hansen, M., & Lip, G.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2012
- Volume
- 107
- Issue
- 06
- Pages
- 1172-1179
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2070601915
- Cited by
- 485
- References
- 40
- FWCI
- 41.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.